Convalescent Plasma Trials Update

01/12/2020

Total number of patients randomised:

7,235

- Latest hospital to open:

Grange University Hospital (Wales)

- Highest recruiting hospital:

Russells Hall (79 patients)

REMAP-CAP
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia

- Latest hospital to open:

Broomfield Hospital

- Highest recruiting hospitals:

University Hospitals Leicester (200 patients)

RECOVERY
Randomised Evaluation of COVID-19 Therapy

RECOVERY trial update from Professor Peter Horby (Chief Investigator):

- It has been fantastic to work with NHSBT and I'm aware that there's a huge effort to get this done.
- We've had to move fast and have now moved into more specific therapies – CP is one we are excited about for a number of different infections.
- RECOVERY is easily biggest CP trial ever and it is our one chance to have a definitive trial. We'd also like to keep going until we have a definitive answer.
- As a result, we can't yet predict an end date which depends on recruitment and on outcomes, e.g mortality rate, which is declining.
- If it is proven to work, the beauty of CP is that it's a technology which can be used in any setting, anywhere across the world.
- There is huge international interest in this trial from the US and Asia – whatever the result, it will be immensely influential.

Convalescent Plasma Trials Update

01/12/2020

RECOVERY

Randomised Evaluation of COVID-19 Therapy

- Start Date: **26/05/2020**
- Number of hospitals open: **218**
- Number of patients randomised: **6,222**

- Further information about the trial: www.recoverytrial.net

SUMMARY OF TRIAL INCLUSION CRITERIA

- Hospitalised (any age)
- SARS-CoV-2 infection (clinically suspected or laboratory confirmed)
- No medical history that might put the patient at significant risk if he/she were to participate in the trial

REMAP-CAP

Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia

- Start Date: **30/04/2020**
- Number of hospitals open: **121**
- Number of patients randomised: **1,013**

- Further information about the trial: www.remapcap.org

SUMMARY OF TRIAL INCLUSION CRITERIA

- Adults admitted to an Intensive Care Unit
- SARS-CoV-2 infection (laboratory confirmed)
- No medical history that might put the patient at significant risk if he/she were to participate in the trial